Company News: Curetis Reports Financial Results for the First Six Months of 2016

Friday, August 19, 2016

- Key business and commercial milestones and goals met

- Global presence further strengthened with subsidiaries in the U.S., UK, France and the Netherlands

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first six months ended June 30, 2016, and provided an update on its financial and business guidance for the second half 2016 and beyond.


Operational and Business Highlights 2016 to Date

Company News: Agena Bioscience Expands ISO Accreditation for Genetic Testing

Tuesday, August 16, 2016

Agena Bioscience today announced accreditation of its Assays by Agena facility in Brisbane, Australia, under ISO/IEC 17025 in the field of biological testing for determinations of SNP Genotyping, somatic mutation detection, and quantitative methylation analysis using its MassARRAY® System.

The accreditation comes from the National Association of Testing Authorities, or NATA, and ensures that member facilities comply with standards and provide accurate data generation, controlled test methods and procedures, and properly trained personnel.

Agena Bioscience CEO Peter Dansky commented, “Accreditation of our facility in Brisbane demonstrates the company’s commitment to advance the MassARRAY System into the clinical market, and ensure consistent, valid, and robust results under documented quality management systems.”

Company News: Curetis to Report its Half-Year Results 2016 on August 19, 2016

Monday, August 1, 2016

- Company will host earnings conference call and webcast

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it will publish its financial results for the first six months ended on June 30, 2016, on August 19, 2016. In addition, the Company will host a public earnings conference call and webcast on August 19, 2016, at 03:00 pm CET / 09:00 am EST to present the H1 2016 financial results, highlight the most important events and provide an outlook for the second half of 2016 and beyond.

The conference call will be supplemented by a presentation, which can be accessed during the call at through the participants’ passcode curetis0816. The live webcast and a replay will be available at

Company News: New CELL Study presents groundbreaking pre-clinical work: developing immune therapy to potentially treat serious influenza A

Thursday, July 21, 2016

- MEDI8852 blocked all influenza A with unique binding properties

A paper published today by Cell presents pre-clinical work to develop a promising new antibody, MEDI8852, as a potential therapy to treat influenza caused by numerous type A strains – the source of seasonal and pandemic outbreaks. The findings also highlight the mechanisms of action of MEDI8852, which along with its unique binding properties, point to valuable implications for the design of a universal influenza vaccine that can address the unpredictable nature of the flu virus.

“The results of this study confirm how MEDI8852’s unique molecular features have the potential to differentiate it from current treatment options for influenza, with the potential to become an important anti-influenza candidate during pandemic periods,” said JoAnn Suzich, Vice President, R&D, MedImmune.

Company News: Molecular Health Strengthens U.S. Based Executive Management Team

Thursday, July 21, 2016


- Appoints Gerry Sheridan as Chief Financial Officer

- Appoints Dr. Les Paul as Chief Medical Officer

Molecular Health, a leader in precision medicine technology focused on commercializing products utilizing its proprietary Dataome™ technology platform, today announced it has strengthened its leadership team with the appointment of two U.S.-based executives. Gerry Sheridan will serve as Chief Financial Officer and Dr. Les Paul as Chief Medical Officer. Mr. Sheridan and Dr. Paul will be based in the Company’s U.S. headquarters in Boston to facilitate the Company’s expansion into the U.S. commercial markets and building of an expanded U.S. operational infrastructure.